

Endocytic network of human dendritic cell upon T cell recognition.
live cell confocal lsm
T cell mitochondria (orange) shaped by cytoskeleton (green) next to nucleus (blue).
3D SIM

Clusters of T cell receptor molecules
at the site of cell-cell communication. PALM

T cell actin (green) and microtubule (magenta) remodelling during cell-cell contact.
LLSM

T cell mitochondria.
Expansion microscopy
Reconstructive Immunotherapy
Eliminate pathology. Enable repair. Sustain tissue health.
I’m Ewoud B. Compeer, an immunologist working at the intersection of immune cell biology and therapeutic innovation. I study how immune cells organise, communicate and function, and how these mechanisms can inform the design of living medicines.
My ambition is to establish Reconstructive Immunotherapy: a research programme that brings selective disease elimination, tissue repair and durable immune regulation into one therapeutic strategy.
​
From cellular mechanisms to living therapies
My research connects antigen presentation and endosomal remodelling with T-cell receptor trafficking, immune synapses and metabolic control of immunity. First-author work identified a mobile endocytic network that supports T-cell activation, building on studies of antigen cross-presentation in human dendritic cells.
Collaborative studies extend this work to T-cell fitness, extracellular-vesicle imaging, regulatory T-cell metabolism and cytotoxic supramolecular attack particles. Recent research examines how lipids in ovarian cancer ascites disrupt TCR dynamics and impair T-cell activation.
Together, these studies connect the organisation of an immune cell with its ability to act within a diseased tissue.
​
A programme with three connected goals
ELIMINATE PATHOLOGY
Identify and selectively target the cells and interactions that sustain pathological tissue environments.
ENABLE RECONSTRUCTION
Combine disease control with signals that engage endogenous repair and support the recovery of tissue organisation and function.
SUSTAIN HOMEOSTASIS
Establish tissue-appropriate immune regulation and surveillance to help maintain health over time.
​
CyTrex: connecting regulation and effector function
My work on CD8 regulatory T cells provides a foundation for investigating multifunctional immune therapies. Our 2026 preprint reports human CD8 induced regulatory T cells with both GVHD-suppressive and tumouricidal functions, involving granzyme-K-positive supramolecular attack particles.
This emerging work motivates a broader question: how can therapeutic immune cells combine precise effector activity with immune regulation and support for tissue recovery? The preprint has not yet been peer reviewed, and tissue reconstruction remains an objective for the proposed programme.
​
High-grade serous ovarian cancer as a starting point
​
High-grade serous ovarian cancer (HGSOC) provides a compelling starting point for Reconstructive Immunotherapy. Its immunosuppressive tumour microenvironment, frequent peritoneal dissemination and high recurrence burden highlight the limitations of disease elimination alone. Building on my research into lipid-mediated T-cell suppression and multifunctional cytotoxic immune cells, I aim to develop therapeutic strategies that overcome local immune dysfunction while selectively eliminating malignant cells.
​
My proposed programme will integrate spatial and single-cell profiling, mechanistic immunology and immune-cell engineering to identify disease-sustaining cellular networks and develop interventions that combine tumour clearance with restoration of tissue immune balance. Success will be evaluated not only through tumour elimination but also through the recovery of immune function, resolution of pathological tissue interactions and establishment of durable immune surveillance.
HGSOC will serve as the initial disease model for developing principles of Reconstructive Immunotherapy, with the longer-term ambition of extending these approaches to other solid tumours and chronic diseases.
​
Building the field together
Reconstructive Immunotherapy brings together mechanistic immunology, cancer biology, cellular engineering, spatial biology and regenerative medicine. Starting with high-grade serous ovarian cancer, my ambition is to establish a collaborative research programme that moves beyond eliminating disease towards restoring tissue function and durable immune balance.
​
I welcome conversations with academic institutions, clinicians, biotechnology leaders and research partners interested in developing the next generation of living immunotherapies.
​
Research case studies · Leadership and impact · Discuss a collaboration

RECENT ARTICLES
Lipids in ovarian cancer ascites impair T cell activation by disrupting TCR dynamics
Brown, Compeer and colleagues · Nature Metabolism · 2026
Human CD8-iTreg are potent GVHD suppressors and tumoricidal effectors by release of Granzyme-K+ Supramolecular Attack Particles
Larson, Compeer and colleagues · bioRxiv · 2026 · Preprint; not yet peer reviewed
